Phase 1 Clinical Pharmacology Studies.
Abstract
Six Phase I clinical pharmacology studies were performed during this contract period under the Task Order numbers 90-01, 92-04, 92-05, 94-06, 94-07 and 94-09. Task Order 90-01 produced data suggesting that the Mark I auto-injector produced effective and desirable blood levels and effects of atropine and 2-PAM compared to other prototype auto-injectors. Task Order 92-04 demonstrated that WR 238, 605 was safe and well tolerated at single doses up to 600 mg. Task Order 92-05 compared the blood levels produced by a new dosing regimen for halofantrine in the fed compared to the fasting state. Task Order 94-06 demonstrated the lack of irritating potential for a topical skin protectant. Task Order 94-07 demonstrated the safety of weekly dosing with the antimalarial WR 238, 605 and documented the accumulation of non toxic methemoglobin levels at the higher doses. This side effect may be beneficial in prophylaxis against cyanide poisoning. Task Order 94-09 showed a lack of toxicity from multiple dose pyridostigmine bromide in healthy male and female subjects of different weights.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA331019
Entities
People
- Kenneth C. Lasseter